Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Alright, alright - here it is...hint, I'm the pretty one.
http://www.investorshub.com/boards/board.asp?board_id=373
OT: I'll be interested in this.
Hee, hee! No way, I'm not that naive! Funny things have been known to happen to pictures posted on Ihub...
I do like the one of you with your "new" bike. Do you still have it?
OT: There's an interesting new board on Ihub where you post why you chose your alias or what it means to you. It's fun seeing why people chose the names they did. If you're interested (and there's many here I would love to know the rhyme and reason behind) here's the link:
http://www.investorshub.com/boards/board.asp?board_id=8465
Very nice board.
Rocky is a nickname from highschool and 822 is my birthday.
It's funny, like Jski, the first time I signed up for an alias on the internet it offered suggestions i.e. a nickname. So, I chose this old nickname which is a play off of my first name.
Well, it just didn't occur to me that most people would think Rocky Balboa from the Rocky movies and assume I was male (which I'm not).
OH MY!!! Guilt free doughnuts - wooohooo!
Hee, hee - just had some potatoes for breakfast - maybe even better the next day! Can't wait to try the pot stickers!
Have a great day.
LOL! (And, just so you know "herself").
WOW! Those were delicious potatoes! Great recipe - thank you for sharing it with us.
You didn't answer the door so I left them on the front porch - hope the neighborhood cats don't get the shrimp. :)
Potatoes in the oven and they smell soooooo good.
Thanks, leaving now. I'll let you know how they turn out!
I was planning on having these tonight, went to the store this morning and forgot the Swiss cheese. I have mozarella, what do you think...can I use that or do I need to go get some Swiss? I also have Feta but I don't think that would work, would it? I realllly don't want to go back to the store.
As you can see, not a very experienced cook but love good food. Any advice would be appreciated.
Wow, this is just getting worse as each days passes.
Check out this "Hamdog" apparently served at the same restaurant. EWWWWWWWWWWWWWWWWWWWWWWWWW!
http://www.snopes.com/food/origins/luther.asp
Edit: Churak, you beat me to it!
Have you heard about those Dunkin Donuts burgers? I can't find the link right now but some restaurant serves burgers with Dunkin Donuts as the bun. Can you imagine eating such a thing?
Smart woman. :)
Ewwwwww! Have you tried those?
Decoding the 39 Ingredients in a Twinkie
A new book 'deconstructs' a Twinkie and analyzes all 39 ingredients. Industrial-strength junk food, anyone?
By Anne Underwood
Newsweek
March 5, 2007 issue - As Steve Ettlinger dropped down a Wyoming mine shaft, plummeting 1,600 feet in an open-mesh cage, he wondered how many other food writers had ever donned hard hats and emergency breathing equipment in pursuit of a story. But it was too late to turn back. He'd promised his editor a book tracing the ingredients in a Hostess Twinkie to their origins—and one of them was down this shaft. At the bottom, he and his hosts climbed into an open Jeep and hurtled for 30 terrifying minutes through pitch-black tunnels. Their destination: the site where a mineral called trona—the raw ingredient of baking soda—was being clawed out of a rock face by giant machines. "To say that this does not suggest Twinkies or any other food product would be an understatement," observes Ettlinger. "There you are at an open rock face, wondering why they do all this for the sake of a little snack cake."
If you've ever puzzled over why packaged foods contain "polysorbate 60" or "mono and diglycerides," Ettlinger's new book, "Twinkie, Deconstructed," is a treat you'll want to try. Chapter by chapter, Ettlinger—the author of previous food books like "Beer for Dummies"—decodes all 39 ingredients in the little crème-filled cakes. He explains their uses and the processes by which raw materials are "crushed, baked, fermented, refined and/or reacted into a totally unrecognizable goo or powder with a strange name," which then appears on a label full of other incomprehensible and barely pronounceable ingredients. Unraveling it all was a major undertaking—and Ettlinger received no help from Hostess and its parent company, Interstate Brands Corp., despite appealing directly to the Vice President of Cake.
At the heart of the book is the fundamental question: why is it you can bake a cake at home with as few as six ingredients, but Twinkies require 39? And why do many of them seem to bear so little resemblance to actual food? The answer: To stay fresh on a grocery-store shelf, Twinkies can't contain anything that might spoil, like milk, cream or butter. Once you remove such real ingredients, something has to take their place—and cellulose gum, lecithin and sodium stearoyl lactylate are a good start. Add the fact that industrial quantities of batter have to pump easily through automated tubes into cake molds, and you begin to get the idea.
Even so, it can be unsettling to learn just how closely the basic ingredients in processed foods resemble industrial materials. Corn dextrin, a common thickener, is also the glue on postage stamps and envelopes. Ferrous sulfate, the iron supplement in enriched flour and vitamin pills, is used as a disinfectant and weedkiller. Is this cause for concern? Ettlinger says no, though you wouldn't want a diet that consists solely of Twinkies. Ultimately, all food, natural and otherwise, is composed of chemical compounds—and normal ingredients like salt have industrial applications, too. Still, it gives you pause when he describes calcium sulfate, a dough conditioner, as "food-grade plaster of Paris."
In the end, you may learn more than you really wanted to about the Twinkie-Industrial Complex, as Ettlinger calls it. But you will never read a label the same way again.
URL: http://www.msnbc.msn.com/id/17303919/site/newsweek/
--------------------------------------------------------------------------------
I've never tried this but it was posted here awhile ago and I save it. Glty.
http://www.investorshub.com/boards/read_msg.asp?message_id=16824198
That's a good one! Have a great weekend, OU!
Hee, hee! Maybe...
Just never realized there were so many interesting options for men's underwear these days - having I been living in a cave?
Have a great weekend, all!
Have you seen this? :)
Men’s Underwear Gets a Fashion Boost
Skivvy sales did, so designers stole Victoria's secrets.
WEB EXCLUSIVE
By Ramin Setoodeh
Newsweek
Updated: 5:13 p.m. ET Feb 13, 2007
Feb. 13, 2007 - Arnie Bautista buys designer underwear by the bunch. "For me, it's an investment," says the 31-year-old advertising executive from New York. "I like to look really good out of my clothes." He spends up to $350 a season on expensive stretchy shorts from brands like 2xist ("to exist"), Calvin Klein and Ginch Gonch, a Canadian retailer that sells little briefs with prints of stars and firetrucks. He has 50 or 60 pairs—so many, that he's run out of shelf space for all those drawers. About the only kind of undies he doesn't own? "I don't wear Fruit of the Loom," he says.
It wasn't long ago that guys had only two choices in the morning: boxers or briefs, usually both in white. But in a metrosexual age, sexy skivvies in a rainbow of colors have become the hot new fashion accessory. Much like Victoria's Secret and Frederick's of Hollywood did with women's lingerie in the '80s, upstart companies like 2xist and C-in2 (pronounced "see into"), along with stalwarts like Jockey and Calvin Klein, are selling designer (read: pricey) undies to the masses—and raking in the bucks.
In a slumping fashion market, sales of men's undergarments climbed 14 percent to $3.6 billion last year from $3.1 billion in 2004, according to the market research firm NPD Group. Sales of women’s panties were up only 7.7 percent, to $3.1 billion from $2.9 billion in 2004. (Of course, those figures don't include other undergarments women buy, including bras.) Scores of companies, including most of the big designer labels, are now into men's underwear, compared to just a handful of players a decade ago: FreshPair, a top selling site for shorts on the Web, carriers 37 different brands. Most telling of all: 67 percent of men buy their own underwear now. It used to be that 80 percent of men's underwear was purchased by women, reports industry leader Jockey.
Thank "Queer Eye for the Straight Guy" and its ilk for making men more willing to get their sexy on. Julie Hornburg, director of sales for intimates at Diesel, says men have begun to consider underwear an "event purchase"—something special to don on Saturday night. "They want to have nice underwear on, for when they finally drop their pants," she says. Helping guys look sexier with pants on is also a big selling point. "We have a customer from Wall Street that swears by our thong because he doesn't want a visible panty line," says Jason Zambuto, cofounder of C-in2, which packages its briefs in colors named after food flavors like blueberry and limeade. C-in2's "Sling" brief provides a lift similar to the Wonder Bra and has been a major hit since its introduction two years ago, with 500,000 pair sold in stores like Saks and Bloomingdale's. This year, C-in2 unveiled a marvel of underwear engineering that's even more gravity-defying: the Trophy Shelf.
Indeed, companies are devising ever more exotic—and expensive—offerings. Dolce & Gabbana sells camouflage "Combat" briefs for $38 a pair. Paul Frank can suit you up with "Butt huggers" for $28. And men who sip soy lattes can now pick up soy shorts from 2xist. No, they're not edible, but they're "environmentally friendly," UV protected, and they'll set you back $20 a pair. "It feels like cashmere," company designer Jason Scarlatti says of the briefs, which are made from soybean fibers and spandex. The success of the racy upstarts has the giants adjusting their shorts. "The consumers are more knowledgeable," says Paula Barnes, director of men's merchandising at Jockey, "and they are paying attention to additional features." Jockey recently introduced a new "3D innovations" line, at $14 a brief, that stretches in eight different directions (don't ask). The spring line comes in wild colors, including three shades of orange, a hue that's usually a tough sell in men's undies. Jockey is also slowly weaning gents from two industry standards: the color white, and the fly. Today, 38 percent of the underwear it sells is colored, and 15 percent is flyless. "Our consumer research tells us there is a customer out there who doesn't use the fly and doesn't want the fly," says Barnes. Those must be the same guys who want the Trophy Shelf.
http://www.msnbc.msn.com/id/17136752/site/newsweek/
That was my favorite, too - I truly laughed out loud on that one. Have a good day, Bridget!
WEDC - $6.72 Great call on this one, Bridget!
I would love to see standard information (company address, phone, number, share structure, transfer agent etc.) in a set format at the top of the Ibox. Then an area below that for other information the moderators would like to add would be fine.
This one moving nicely, too - WEDC $6.50
I take it I'm not alone in that 1/2 second - 3 seconds of insanity I experience multiple times on a daily basis as of now?
Someone on one of the boards was advocating everyone "tos" a poster for spam because he repeated the same thing at the end of every post that had nothing to do with the company. LOL!
I remember Dane joining in on that one and even complimenting Oiliphant on his sense of humor. I'll have to search and see if I'm remembering correctly.
My impression was that Dane took exception to the inaccuracies and/or unprovability (?) of Oiliphant's predictions and other's reactions to these posts.
In fact, I believe that Oiliphant posted that picture BECAUSE Dane was searching for validity...Not that Dane became any more skeptical BECAUSE of that picture.
JMHO
Edit:
http://www.investorshub.com/boards/read_msg.asp?Message_id=15573667&txt2find=butt
Great suggestion.
Tryoty, here's info on the other two owners of Starcrest. I don't know what sort of political pull (if any) they have.
http://www.investorshub.com/boards/read_msg.asp?Message_id=14869959&txt2find=starcrest
Sure, sorry I didn't include the link the first time. :)
http://biotech.seekingalpha.com/article/27597
Investing in Stem Cell Stocks: Growth Industry of the Future?
Posted on Feb 21st, 2007 with stocks: ACTC.OB, ALXN, ARIA, ASTM, AVII, CCEL.OB, CELG, CRA, CRIS, IART, IVGN, KOOL, LIFC, OPXA, OSTE, STEM, VIAC
Stockerblog submits: Last Friday, the state of California distributed $45 million in research grants to approximately 20 state universities and nonprofit laboratories for stem cell research.
Four other states, Connecticut, Illinois, Maryland, and New Jersey, are also funding stem cell research. California is contributing almost twice as much as the Federal government towards research. Arnold Schwarzenegger, Governor of California, said "Today, we are making history."
According to StemCellsStocks.com, the research into stem cells involves finding out how an organism develops from a single cell and how healthy cells replace damaged ones. This research can lead to cell-based therapies to treat various diseases.
The difference between stem cells and other cells is that they renew themselves for long periods of time from cell division and they can be made to become cells with special functions. Embryonic stem cells, as opposed to adult stem cells, are isolated stem cells from human embryos that are grown in labs. The embryos used in this research were produced for infertility purposes through in vitro fertilization and later donated for research with the donor’s consent. Research is being done to treat diseases such as Parkinson's disease, diabetes, and heart disease.
There are only a limited number of stocks which are pure plays or semi-pure plays in the stem cell industry. However, if governmental funding increases, if private research continues, and if there are any major breakthroughs, this could be a very huge industry. The following list also includes cord blood stocks, a related industry.
Aastrom Biosciences (ASTM): This Michigan based company is involved in the development of cell products for the regeneration or repair of human tissues, based on its proprietary Tissue Repair Cell [TRC] technology. Negative earnings, price/sales ratio is 211.
Advanced Cell Technology (ACTC.OB): This company is involved in the development and marketing of human stem cell technology in the area of regenerative medicine and stem cell therapy. Negative earnings, P/S is 64.
Alexion Pharmaceuticals (ALXN): This Connecticut based company is involved in the development of biologic therapeutic products for the treatment of hematologic and cardiovascular disorders, autoimmune diseases, and cancer. Negative earnings, P/S is 864.
ARIAD Pharmaceuticals (ARIA): This Massachusetts company is involved in the development of medicines for the treatment of cancer by regulating cell signaling with small molecules. Their cancer products are used to treat sarcomas, hormone refractory prostate cancer, and endometrial cancer. Negative earnings, P/S is 367.
AVI Biopharma (AVII): The Oregon based company is involved in the development of therapeutic products based on NEUGENE antisense technology to treat various diseases. Negative earnings, P/S is 100.
BioTransplant [BTRNQ.PK]: This company is involved in the development of therapeutics, therapeutic devices, and therapeutic regimens designed to suppress undesired immune responses, and enhance the body’s ability to accept donor cells, tissues, organs, and stem cell transplants. Negative earnings, P/S is .6.
Brainstorm Cell Therapeutics [BCLI.OB]: This New York based company develops stem cell therapeutic products based on technologies which facilitate the in vitro differentiation of bone marrow stem cells from neural-like cells. They use bone marrow stem cells to produce neuron-like cells for the treatment of multiple sclerosis, Parkinson's disease, and other diseases. No earnings, no revenues.
Celera Group (CRA): This NYSE company, founded in 1937, is involved in the discovery and validation of new diagnostic markers, using proprietary genomics and proteomics discovery platforms and diagnostic products based on those markers. They collaborate with Abbott Laboratories (ABT), Genentech (DNA), General Electric (GE) and Merck (MRK). Negative earnings, P/S is 24.
Cellgene (CELG): This New Jersey company is involved in the discovery, production, and marketing of therapies designed to treat cancer and immune-inflammatory-related diseases. Their primary product includes THALOMID, for the treatment of erythema nodosum leprosum. Last year, the company received patent on placental stem cell recovery. P/E is 316, P/S is 21.
Cord Blood America [CBAI.OB]: This Los Angeles company is involved in the collection, testing, processing, and preservation of the blood from umbilical cords for use in future stem cell therapy. Negative earnings, P/S is 1.7.
Cryo-Cell International (CCEL.OB): This is a Florida based family cord blood stem cell bank. P/S is 1.7.
Curis, Inc. (CRIS): This Massachusetts based company is involved in the discovery, development, and marketing of products that modulate key regulatory signaling pathways which control the repair and regeneration of human tissues and organs. It collaborates with Genentech, Procter & Gamble (PG), and Wyeth (WYE). Negative earnings, P/S is 4.9.
Dendreon Corporation (DNDN): This company is involved in the discovery, development, and marketing of active immunotherapies, monoclonal antibodies, and small molecule product candidates to treat cancer. They manufacture the DACSÒSC stem cell enrichment device. Negative earnings, very high P/S of 1500.
Geron (GERN): This Menlo Park, California company develops cell-based therapies derived from human embryonic stem cell platforms for treatment of various diseases. Negative earnings, P/S is 186.
Integra Lifesciences Holdings (IART) This New Jersey company develops, manufactures, and sells medical devices, implants, biomaterials, and instruments to the neurosurgery, surgery, and soft tissue repair markets. P/E 45, P/S 3.4.
Invitrogen Corporation (IVGN): This California company sells products and services which support academic and government research institutions, pharmaceutical companies and biotechnology companies, including tools for gene acquisition, gene cloning, gene expression, and gene analysis techniques. Negative earnings, P/S is 2.6.
LifeCell Corporation (LIFC): This New Jersey company develops and sells human-derived tissue-based products for use in reconstructive, orthopedic, and urogynecologic surgery. They produce a three-dimensional structured regenerative human tissue matrix. P/E 45, P/S 6.3.
MedImmune (MEDI): This Maryland company develops, manufactures, and markets products for the treatment of infectious diseases, inflammatory diseases, and cancer. P/E 167, P/S 6.2.
MultiCell Technologies [MCET.OB]: The company develops and markets therapeutics based on new drug candidates and patented drug development technology platforms to treat MS-related chronic fatigue, infectious disease, cancer, and autoimmune disease. They also produce immortalized human hepatocyte cell lines. Negative earnings, P/S is 11.2.
Osteotech (OSTE): This New Jersey company processes and distributes allograft bone tissue used for transplants. P/S is 1.3.
Opexa Therapeutics, Inc. (OPXA): This company, based in Texas, develops and markets autologous cellular therapies for the treatment of multiple sclerosis, rheumatoid arthritis, cardiovascular diseases, and diabetes, based on stem cell technologies. No revenues, no earnings.
StemCells Inc. (STEM): This Palo Alto company is involved in the discovery and development of adult stem cell therapeutics for treating damage to the central nervous system, liver, and pancreas. Negative earnings, P/S is a high 1771.
ThermoGenesis (KOOL): This California company designs, manufactures, and markets automated blood processing systems that facilitate the manufacture, preservation, and delivery of cell therapies. P/S 13.6.
ViaCell (VIAC): This Massachusetts company sells ViaCord, a product which is used to preserve a baby's umbilical cord blood. They also research other therapeutic uses of umbilical cord blood-derived and adult-derived stem cells. Negative earnings, P/S is 3.9.
Disclosure: Author does not own any of the above.
Ntd, I absolutely think this Feltang has some connection to the payment ERHC made to Feltang. There's too much coincidence for it to be just that, imo.
I think the question is why does the "company" NOW have a website? Is it in response to something or in preparation for something?
Sight for Sore Eyes
Progress in cell transplants to heal damaged retinas
By Alison Snyder
Millions of photoreceptor cells residing in the human retina gather light and transmit signals to the brain. When these light-collecting cells die, they take the person's sight with them. Medical researchers hoping to reverse blindness have turned their gaze toward stem cells, and recent experiments have shown that these cells could replace photoreceptors lost in macular degeneration.
As the most common form of blindness, macular degeneration affects 10 percent of Americans older than 65 years. It first targets a protective lining called the retinal pigment epithelium (RPE), which shuttles nutrients to the photoreceptor cells and is vital for their survival. A transplant of fresh RPE tissue could rescue dying photoreceptors. But the approach is not feasible considering the large amounts of tissue needed to treat the millions of Americans who show signs of early macular degeneration.
Scientists at the biotechnology firm Advanced Cell Technology in Worcester, Mass., have generated a more abundant source of RPE cells. In 2004 they devised a way to coax embryonic stem cells to turn into transplantable RPE tissue. In a follow-up experiment, they injected the transformed cells into the eyes of rats that had a photoreceptor-killing genetic defect in their RPE cells. As the researchers reported in the September 2006 Cloning and Stem Cells, weeks later, when the effects of the disease would have normally set in, the rats receiving the treatment were able to track stripes on a rotating cylinder twice as well as those that did not. Their vision, though improved, was still far below normal.
But treating patients who have advanced degrees of macular degeneration or other photoreceptor diseases will ultimately require repairing the photoreceptor cells themselves. Last November researchers at University College London and other institutions announced that they had extracted cells from mouse retinas that were at different developmental stages and successfully transplanted them into blind mice. They found that immature photoreceptor cells from healthy newborn mice, rather than embryonic or adult mouse cells, migrated to the correct region of the retina and continued to develop into mature photoreceptor cells. The pupils that received these cells were also more sensitive to light than those that did not receive the transplant.
These findings have suggested the development stages at which to transplant cells--for instance, photoreceptor cells need to be relatively more mature than stem cells, according to Thomas Reh, who studies retinal development at the University of Washington. The human equivalent to the mouse cells, however, would have to be isolated from fetal retinas, posing the familiar problem of finding a source for the immature cells. Adult stem cells and cornea stem cells are two other possible sources for generating immature photoreceptor cells.
In his lab, Reh coaxes human embryonic stem cells into retinal stem cells, and currently about 6 percent of them subsequently turn into photoreceptor cells. That yield may sound small, but a low percentage is not necessarily discouraging, according to Evan Snyder, a stem cell researcher at the Burnham Institute for Medical Research in La Jolla, Calif. By studying what pushes those 6 percent into their fate as photoreceptor cells, researchers might figure out how to generate a larger number of transplantable cells. They might also come up with a way to select the right cells out of a mixed population; Anand Swaroop, an ophthalmology researcher at the University of Michigan at Ann Arbor, is working on a way to identify and weed out the photoreceptor cells by focusing on proteins present on cell surfaces.
Having generated a cell source and overcome the safety concerns associated with transplanting stem cells, researchers still face possibly their biggest challenge: showing that the transplanted photoreceptors wire up to other neurons that eventually connect to the optic nerves. Each photoreceptor must make hundreds of critical connections. "Just because you have the right cell type doesn't mean you have the right circuitry," Snyder says. The immature photoreceptors transplanted from mouse retinas show activity, but Swaroop cautions that behavioral tests must determine that the photoreceptor cells are being repaired. A partial connection could generate the activity seen in the mice's pupils, but true vision improvement depends on the animals' ability to react to color and other visual cues. Seeing, after all, is believing.
Nightdaytrader, this is new. Sllabxam and I searched extensively in early October and this did not come up. One of the links earlier says this was registered 9/22 and one says 12/1 (if I'm reading the info correctly).
In the first link, it's interesting that it has a link to "Wiki" page. Could be that that is a service of the site provider or someone took the time to go in and list an entry.
Lastly, the "gibberish" on the pages is common in marketing and advertising. It just means "content to be provided later".
Just found this but unsure if it tells us anything more. Maybe one of the computer guru's out there can look at and see if they can get anymore info from it.
http://whois.domaintools.com/feltang.com
Edit: This says it was registered on 9/22/06.
http://www.registeredon.com/new/com_060922_0031.html
Ahhhhh, now I understand.
Edit: Well, this is how much of an idiot I can sometimes be - at first, I thought this was a new "breed". LOL! I was confused for awhile then it occurred to me that a human must have shaved/dyed, etc. the cat. I never even thought about the most obvious answer!
Churak, you always make me laugh!
That's so strange, isn't it? It would be unnerving to me to have that cat walking around the house.
I wonder what drives people to do such things? It must be very time consuming to "create".